Clinical Trials
26 trialsNCT06638307 2026-05-12
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
NCT03850873 2026-04-09
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT07101601 2025-08-03
Study of DM5167 in Patients With Advanced Solid Tumors
DIGMBIO
Phase 1 Recruiting
NCT06941142 2025-04-23
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT06710990 2025-03-28
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT06724835 2024-12-09
Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)
Shenzhen Celconta Life Science Co., Ltd.
Phase 1 Unknown
NCT04728035 2024-07-26
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT06290466 2024-03-04
Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects
Ahon Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02599363 2023-11-09
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT06098599 2023-10-24
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
Luye Pharma Group Ltd.
Phase 1 Completed
NCT06047184 2023-09-21
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
BeBetter Med Inc
Phase 1 Unknown
NCT04097756 2023-05-01
A Phase I Study of LX-039 Tablets
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 1 Completed
NCT02027376 2023-04-03
EDALINE
Spanish Breast Cancer Research Group
Phase 1 Completed
NCT05337657 2022-04-20
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
Genor Biopharma Co., Ltd.
Phase 1 Unknown
NCT05274893 2022-03-11
A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04856371 2021-04-23
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Haihe Biopharma Co., Ltd.
Phase 1 Unknown
NCT02952729 2021-02-24
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
Mersana Therapeutics
Phase 1 Completed
NCT03125746 2021-01-05
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 1 Unknown
NCT03282825 2018-01-23
Clinical Study of Decitabine and Paclitaxel Combination Therapy
Dong Wha Pharmaceutical Co. Ltd.
Phase 1 Unknown
NCT00719875 2017-03-03
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Yale University
Phase 1 Completed
NCT00452673 2015-03-24
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00106145 2015-01-30
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01931943 2013-08-30
A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT00328120 2010-11-17
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
AstraZeneca
Phase 1 Completed
NCT00915369 2010-02-08
A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer
Fresenius Kabi Oncology Ltd.
Phase 1 Unknown